Partial response to Chinese patent medicine Kangliu pill for adult glioblastoma: A case report and review of the literature
Ge Sun, Wei Zhuang, Qing-Tang Lin, Lei-Ming Wang, Yu-Hang Zhen, Sheng-Yan Xi, Xiao-Lan Lin
Ge Sun, Wei Zhuang, Lei-Ming Wang, Xiao-Lan Lin, Department of Pharmacy, Xuanwu Hospital of Capital Medical University, Beijing 100053, China
Qing-Tang Lin, Yu-Hang Zhen, Department of Neurosurgery, Xuanwu Hospital of Capital Medical University, Beijing 100053, China
Sheng-Yan Xi, Department of Traditional Chinese Medicine, School of Medicine and Cancer Research Center, Xiamen University, Xiamen 361102, Fujian Province, China
Author contributions: Sun G, Zhuang W and Lin QT were responsible for the study design, data collection, data analysis and interpretation; Sun G was responsible for composing the manuscript; Wang LM was responsible for pathological data collection, analysis, and interpretation; Zhen YH analyzed and interpreted the neuroimaging findings; Xi SY was responsible for English and grammar corrections, critical revisions, and approved the final version; Xi SY and Lin XL were responsible for acquisition, analysis, or interpretation of data, revision for important intellectual content, final approval of the version for publication, and agreed to be accountable for all aspects of the work related to its accuracy and integrity. All authors contributed to the article and approved the submitted version.
Supported by the Foundation for Beijing Science and Technology Development of TCM, No. JJ2016-10; and the National Traditional Chinese Medicine Innovative Talents Training Project from Beijing Municipal Science and Technology Commission, No. Z171100001717006.
Informed consent statement: Written informed consent was obtained from the patient for publication of this report.
Conflict-of-interest statement: The authors report no conflicts of interest. The authors are solely responsible for the content and writing of the paper.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
http://creativecommons.org/Licenses/by-nc/4.0/ Corresponding author: Xiao-Lan Lin, Chief Pharmacist, Reader (Associate Professor), Department of Pharmacy, Xuanwu Hospital of Capital Medical University, No. 45 Changchun Street, Beijing 100053, China.
xllin83@163.com
Received: November 16, 2020
Peer-review started: November 16, 2020
First decision: December 30, 2020
Revised: January 13, 2021
Accepted: February 22, 2021
Article in press: February 22, 2021
Published online: April 26, 2021
Processing time: 147 Days and 20.4 Hours
